But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
But with Derm Assist available free, how will the company make money?
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Key catalysts approach for Orphazyme, Gemini and Immutep.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.